Bicara Therapeutics (BCAX) financial statements
Net income was -$138M.
Free cash flow was -$107M.
The diluted share count rose 9325% over the period (dilution).
Income statement
Fiscal years, from Bicara Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Research and development | $31M | $64M | — |
| Selling, general and admin | $9M | $19M | $31M |
| Operating income | -$40M | -$82M | -$156M |
| Pre-tax income | -$52M | -$68M | -$138M |
| Income tax | $5,000 | $187,000 | $217,000 |
| Net income | -$52M | -$68M | -$138M |
| EPS (diluted) | -$89.61 | -$4.05 | -$2.52 |
| Diluted shares | 580M | 16.81B | 54.68B |
Balance sheet
Fiscal years, from Bicara Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $230M | $490M | $415M |
| Total current assets | $231M | $503M | $422M |
| Property, plant and equipment | $202,000 | $155,000 | $330,000 |
| Total assets | $234M | $510M | $431M |
| Total current liabilities | $15M | $18M | $29M |
| Total liabilities | $15M | $18M | $30M |
| Shareholders' equity | -$149M | $492M | $401M |
| Net debt | -$230M | -$490M | -$97M |
Cash flow
Fiscal years, from Bicara Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -$46M | -$75M | -$107M |
| Capital spending | $586,000 | $71,000 | $280,000 |
| Free cash flow | -$46M | -$75M | -$107M |
| Stock-based compensation | $2M | $7M | $15M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BCAX.
Open BCAX in InvestinglyQuestions
How much free cash flow does Bicara Therapeutics generate?
-$107M in fiscal 2025 (operating cash flow minus capital spending).
From Bicara Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.